ClinicalTrials.gg
RecruitingNCT06345703Updated Nov 19, 2024

First-into-human Study of NS-136 in Healthy Subjects

A Phase 1 interventional study of Placebo and NS-136 tablet in Healthy Subjects, sponsored by NeuShen Therapeutics. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-19.

Sponsored by NeuShen Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to exlplore the profile of NS-136 in health conditions. The main questions it aims to answer are:

  • Is NS-136 safe and tolerable in heathy subjects under tested dosing regimen?
  • What is the pharmacokinectic profile of NS-136 in healthy subjects under tested dosing regimen?
02

Conditions studied

  • Healthy Subjects

Keywords

  • muscarinic m4 receptor
03

In context

Lead sponsor

NeuShen Therapeutics is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Study subjects must meet all of the following criteria for study entry:

  1. Healthy males or females aged 18-65 years (inclusive), with a (BMI) between 18.00 and 32.00 kg/m2(inclusive);
  2. Not participated in any other clinical trials within the past 30 days or 5 half-lives of other drugs prior to the screening, whichever is longer;
  3. For women of , a negative pregnancy test is required, and they must agree to use (more details see Appendix 1) from the time of signing the form until at least 90 days after the last dose of investigational product. Male subjects must agree to use adequate contraception from the time of signing the informed consent form until at least 90 days after the last dose of investigational product, and donation of sperm or ova is prohibited during the entire study period;
  4. In good health, determined by the investigator on the basis of medical history, physical examinations, vital signs, 12-lead (12-ECGs), clinical laboratory tests (haematology, urinalysis, blood chemistry). Repeated examination is allowed once at investigator's discretion;
  5. Full understanding of the purpose, nature, procedures of the study, and the potential adverse reactions. Subject voluntarily participates and signs the informed consent form before any study procedures begin.

Exclusion criteria

Exclusion Criteria

Subjects who meet any of the following criteria will be excluded from study entry:

  1. Individuals who are allergic to the product or any of its components, or who are easily allergic at investigator's discretion;
  2. Individuals who are intolerant to venipuncture/venous catheterization or blood fainting or needle phobia;
  3. Positive results for surface antigen (HBsAg), virus antibody (Anti-HCV), antibody (Anti-HIV) during the screening period;
  4. Average daily smoking of more than 5 cigarettes in the 3 months prior to screening, or inability to stop using any tobacco products (including nicotine products) during the trial;
  5. Excessive alcohol consumption or weekly alcohol intake exceeding 14 units of alcohol in the 4 weeks prior to screening (1 unit equals 10 grams of pure alcohol, alcohol content of different alcoholic beverages is indicated by volume ratio, approximately 1 alcohol unit is equal to 35 mL of 50° liquor or 350 mL of 5° beer), or unwillingness to stop drinking alcohol or consuming any products containing alcohol during the trial, or positive alcohol test upon screening and admission (repeated test is allowed once at investigator's discretion);
  6. Excessive intake of tea, coffee, or caffeinated beverages (more than 8 cups/day, 1 cup = 250 mL) in the 3 months prior to screening, or inability to stop consuming any beverages or foods containing caffeine, any beverages or foods rich in purines, or grapefruit and other substances that may affect drug absorption, distribution, metabolism, or excretion during the trial;
  7. History of drug abuse within the past year prior to the first dose, or positive results in a multi-drug urine screening test upon screening period and admission. Repeated test is allowed once at investigator discretion;
  8. History of definite neurological or psychiatric disorders (including epilepsy, migraines, dementia, depression or bipolar disorder, schizophrenia, etc.); history of prolonged ; immunodeficiency or diseases, malignant neoplastic diseases; chronic cardiovascular, hepatic, renal, endocrine, respiratory, hematological (including coagulation), digestive system diseases, cholecystectomy, Gilbert's Syndrome or resolved childhood asthma;
  9. Underwent major surgery within the past 6 months prior to the first dose (such as coronary artery bypass grafting, hepatectomy, gynecological surgery, etc.); occurrence of acute neurological, digestive, respiratory, circulatory, endocrine, hematological, or other systemic diseases that may affect the absorption, distribution, metabolism, excretion, and safety evaluation of the investigational product within 3 months prior to screening judged by investigator;
  10. Donated blood or experienced blood loss ≥400 mL within the 3 months prior to the first dose; difficulties in venous blood collection; planned blood donation during the study or within 1 month after the study;
  11. Use of strong inhibitors or inducers of cytochrome P450 (CYP) 3A4 within 14 days prior to the administration of the investigational drug or anticipated use of strong inhibitors or inducers during the study participation period;
  12. Use of any prescription or non-prescription medications, including herbal and OTC medications within 14 days of dosing, with the exception of paracetamol (≤2 g per day);
  13. Receipt of vaccines within the 4 weeks prior to the first dose of the investigational product;
  14. Cannot tolerate high-fat meals or have special dietary requirements, or cannot adhere to a standardized diet (only for subjects in the FE trial);
  15. Other factors deemed unsuitable for participation in the trial by the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Arm1

    NS-136 SAD Dose 1

    Drug: NS-136 tablet

  • Experimental
    Arm2

    NS-136 SAD Dose 2

    Drug: NS-136 tablet

  • Experimental
    Arm3

    NS-136 SAD Dose 3

    Drug: NS-136 tablet

  • Experimental
    Arm4

    NS-136 SAD Dose 4

    Drug: NS-136 tablet

  • Experimental
    Arm5

    Arm5 NS-136 MAD Dose 1

    Drug: NS-136 tablet

  • Experimental
    Arm6

    Arm5 NS-136 MAD Dose 2

    Drug: NS-136 tablet

  • Experimental
    Arm7

    FE Grp A

    Drug: NS-136 tablet

  • Experimental
    Arm8

    FE Grp B

    Drug: NS-136 tablet

  • Placebo comparator
    Arm9

    NS-136 SAD Dose 1 PBO

    Drug: Placebo

  • Placebo comparator
    Arm10

    NS-136 SAD Dose 2 PBO

    Drug: Placebo

  • Placebo comparator
    Arm11

    NS-136 SAD Dose 3 PBO

    Drug: Placebo

  • Placebo comparator
    Arm12

    NS-136 SAD Dose 4 PBO

    Drug: Placebo

  • Placebo comparator
    Arm13

    NS-136 MAD Dose 1 PBO

    Drug: Placebo

  • Placebo comparator
    Arm14

    NS-136 MAD Dose 2 PBO

    Drug: Placebo

Interventions

  • DrugPlacebo

    NS-136 matching placebo

  • DrugNS-136 tablet

    Investigational product NS-136

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Related Adverse Events

    Time frame: for SAD, day 1-7; for MAD, day 1-26, for FE, day1-14

  2. Main pharmacokinetic parameters

    Vd/F

    Time frame: for SAD, day 1-7; for MAD, day 1-26,

  3. Main pharmacokinetic parameters

    CL/F

    Time frame: for SAD, day 1-7; for MAD, day 1-26,

  4. Main pharmacokinetic parameters

    t1/2

    Time frame: for SAD, day 1-7; for MAD, day 1-26,

  5. Main pharmacokinetic parameters

    Tmax

    Time frame: for SAD, day 1-7; for MAD, day 1-26,

  6. Main pharmacokinetic parameters

    AUC0-∞

    Time frame: for SAD, day 1-7; for MAD, day 1-26,

  7. Main pharmacokinetic parameters

    Cmax

    Time frame: for SAD, day 1-7; for MAD, day 1-26,

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Not decided yet

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Nov 2024, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2024
First posted
Apr 3, 2024
StartActual
Apr 30, 2024
Primary completionEst.
Nov 2024
CompletionEst.
Feb 2025
Last update
Nov 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345703
Lead sponsor
NeuShen Therapeutics
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Apr 30, 2024
Primary completion
Nov 2024 (estimated)
Completion
Feb 2025 (estimated)
Last update
Nov 19, 2024

Study contacts

Chao Zhang, PhD
Contact
chao.zhang@neushen.com
8613918282581
Yangyi Qu, MS
Contact
yangyi.qu@neushen.com
8613262952232
Emir Redzepagic, MD
principal investigator · CMAX Clinical Research Pty Ltd
Xiaolan Yong Chief Pharmacist, BS
principal investigator · Chengdu Xinhua Hospital, China

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion